While Trastuzumab has significantly improved outcome in breast cancer patients, including prolonged progression-free periods and overall survival, a large number (40–60%) of HER2 positive (HER2+) tumors will develop de novo or acquired resistance to Trastuzumab [31]. The gene discussed is ERBB2; the disease is breast carcinoma.